Clinical and biochemical factors associated with insulin therapy in gestational diabetes: The role of OGTT-based groups.

Authors

Libera Troìa, Martina Garassino, Riccardo Bertinato, Caroline Leitao Thomaz, Giulia Turatello, Chiara Airoldi, Alessandro Libretti, Daniela Surico, Valentino Remorgida

Published in

Experimental physiology. Aug 10, 2026. Epub Aug 10, 2026.

Abstract

Gestational diabetes mellitus (GDM) represents one of the most common metabolic disorders of pregnancy. This study aimed to identify clinical and biochemical factors associated with antenatal insulin therapy, focusing on the association with oral glucose tolerance test (OGTT)-based phenotypes. Retrospective observational study among GDM women, divided according to their treatment (nutritional therapy (NT) or insulin therapy). GDM was classified into three phenotypes based on OGTT results: isolated fasting hyperglycaemia (IFH-GDM), isolated post-load hyperglycaemia (IPH-GDM) and combined hyperglycaemia (CH-GDM). Maternal demographic, obstetric and biochemical data were analysed. Multivariable logistic regression analysis was performed to identify factors independently associated with insulin therapy. Among 458 women, 39.3% required insulin therapy. Independent factors associated with the use of insulin therapy included pre-pregnancy obesity (odds ratio (OR) 2.07, 95% CI: 1.21-3.55), spontaneous miscarriage history (OR 1.89, 95% CI: 1.21-2.93), pregestational hypothyroidism (OR 2.63, 95% CI: 1.08-6.42), GDM diagnosis at 24-28 weeks versus earlier diagnosis (OR 0.45, 95% CI: 0.28-0.72), and GDM phenotype. Compared with IFH-GDM, IPH-GDM was associated with a lower risk of insulin therapy (OR 0.51, 95% CI: 0.31-0.84), whereas CH-GDM was associated with a higher risk (OR 1.90, 95% CI: 1.10-3.31). In conclusion, women with fasting and combined hyperglycaemia represent the highest-risk group for insulin therapy. Integrating OGTT-based phenotypes with clinical risk factors was associated with increased likelihood of insulin therapy requirement and may support individualized clinical assessment.

PMID:
42574715
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.